A Blog from the Lymphoma Program at Weill Cornell Medicine and NewYork-Presbyterian
Dr. Ari Melnick Discusses the Challenges of Measuring Tumor Heterogeneity
Earlier this week Dr. Ari Melnick answered another question from Targeted Oncology concerning the challenges associated with measuring tumor heterogeneity in finding new avenues for targeted therapy.
Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.
View all posts by lymphomaprogram
New Developments in Lymphoma 